Although this trial did not investigate whether patients with IgE autoantibodies can better respond to omalizumab than those without, a recent study in bullous pemphigoid, another skin disease with IgE autoantibodies, supported this notion. The gene discussed is IGHE; the disease is bullous pemphigoid.